Impact of genetics on neoadjuvant therapy with complete pathological response in metastatic colorectal cancer: Case report and review of the literature

1Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-E386.FerlayJSoerjomataramIDikshitREserSMathersCRebeloMet alCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015;1365E359E38610.1002/ijc.29210Search in Google Scholar

2Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25(29): 4575-4580.1792555110.1200/JCO.2007.11.0833TomlinsonJSJarnaginWRDeMatteoRPFongYKornpratPGonenMet alActual 10-year survival after resection of colorectal liver metastases defines cureJ Clin Oncol2007252945754580Search in Google Scholar

3André T, Boni C, Mounedji-Boudiaf L, Navarro Μ, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. Ν Engl J Med. 2004; 350(23): 2343-2351.10.1056/NEJMoa032709AndréTBoniCMounedji-BoudiafLNavarroΜTaberneroJHickishTet alOxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerΝ Engl J Med20043502323432351Open DOISearch in Google Scholar

4Fong Y, Former J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999; 230(3): 309-318.FongYFormerJSunRLBrennanMFBlumgartLHClinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999230330931810.1097/00000658-199909000-00004Search in Google Scholar

5Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): A randomised, controlled trial. Lancet. 2008; 37(9617): 1007-11016.NordlingerBSorbyeHGlimeliusBPostonGJSchlagPMRougierPet alPerioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): A randomised, controlled trialLancet200837961710071101610.1016/S0140-6736(08)60455-9Search in Google Scholar

6Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol. 2011; 22(7): 1535-1546.2122833510.1093/annonc/mdq632BokemeyerCBondarenkoIHartmannJTdeBraud FSchuchGZubelAet alEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS studyAnn Oncol201122715351546Search in Google Scholar

7Saltz LB, Clarke S, Diaz-Rubio E, Scheithaure W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase ΙII study. J Clin Oncol. 2008; 26(12): 2013-2019.10.1200/JCO.2007.14.993018421054SaltzLBClarkeSDiaz-RubioEScheithaureWFigerAWongRet alBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase ΙII studyJ Clin Oncol2008261220132019Open DOISearch in Google Scholar

8Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008; 26(11): 1830-1835.1839814810.1200/JCO.2007.13.7679GruenbergerBTamandlDSchuellerJScheithauerWZielinskiCHerbstFet alBevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancerJ Clin Oncol2008261118301835Search in Google Scholar

9Manne U, Jadhav T, Putcha BK, Samuel T, Soni S, Shanmugam C, et al. Molecular biomarkers of colorectal cancer and cancer xisparities: Current status and perspective. Curr Colorectal Cancer Rep. 2016; 12(6): 332-344.2862636110.1007/s11888-016-0338-1ManneUJadhavTPutchaBKSamuelTSoniSShanmugamCet alMolecular biomarkers of colorectal cancer and cancer xisparities: Current status and perspectiveCurr Colorectal Cancer Rep2016126332344Search in Google Scholar

10Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007; 18(2): 299-304.17060484Rubbia-BrandtLGiostraEBrezaultCRothADAndresAAudardVet alImportance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgeryAnn Oncol200718229930410.1093/annonc/mdl386Search in Google Scholar

11Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy; myth or reality? J Clin Oncol. 2008, 26(10): 1635-1641.1837589210.1200/JCO.2007.13.7471AdamRWichertsDAdeHaas RJAloiaTLeviFPauleBet alComplete pathologic response after preoperative chemotherapy; myth or reality?J Clin Oncol2008261016351641Search in Google Scholar

12Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12): 1208-1215.10.1016/S1470-2045(13)70447-924120480NordlingerBSorbyeHGlimeliusBPostonGJSchlagPMRougierPet alPerioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trialLancet Oncol2013141212081215Open DOISearch in Google Scholar

13Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010; 17(2): 492-501.1985602810.1245/s10434-009-0781-1ChuaTCSaxenaALiauwWKokandiAMorrisDLSystematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastasesAnn Surg Oncol2010172492501Search in Google Scholar

14Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal [liver] metastases. Ann Surg Oncol. 2001; 8(4): 347-353.10.1007/s10434-001-0347-3AdamRAvisarEAricheAGiachettiSAzoulayDCastaingDet alFive-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal [liver] metastasesAnn Surg Oncol200184347353Open DOISearch in Google Scholar

15Small RM, Lubezky N, Shmueli E, Figer A, Aderka D, Nakache R, et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009; 99(2): 93-98.1906563710.1002/jso.21207SmallRMLubezkyNShmueliEFigerAAderkaDNakacheRet alResponse to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapyJ Surg Oncol20099929398Search in Google Scholar

16Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol. 2015; 22(3): 908-915.2546537510.1245/s10434-014-4094-7UetakeHYasunoMIshiguroMKameokaSShimadaYTakahashiKet alA multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808)Ann Surg Oncol2015223908915Search in Google Scholar

17Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010; 17(8): 2059-2065.2017779510.1245/s10434-010-0972-9KlingerMTamandlDEipeldauerSHackerSHerbergerBKaczirekKet alBevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOXAnn Surg Oncol201017820592065Search in Google Scholar

18Ayez N, Lalmahomed ZS, van der Pool AE, Vergouwe Y, van Montfort K, de Jonge J, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011; 18(10): 2757-2763.2163809310.1245/s10434-011-1819-8AyezNLalmahomedZSvander Pool AEVergouweYvanMontfort KdeJonge Jet alIs the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?Ann Surg Oncol2011181027572763Search in Google Scholar

19Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today. 2015; 45(12): 1527-1534.2556358810.1007/s00595-014-1108-9SchreckenbachTMalkomesPBechsteinWOWoesteGSchnitzbauerAAUlrichFThe clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasisSurg Today2015451215271534Search in Google Scholar

20Balachandran VP, Arora A, Gonen M, Ito H, Turcotte S, Shia J, et al. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases. Clin Cancer Res. 2016; 22(10): 2575-2582.2673361310.1158/1078-0432.CCR-15-1071BalachandranVPAroraAGonenMItoHTurcotteSShiaJet alA validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastasesClin Cancer Res2016221025752582Search in Google Scholar

21Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review andmeta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9(10): 962-972.10.1016/S1470-2045(08)70206-7LinardouHDahabrehIJKanaloupitiDSiannisFBafaloukosDKosmidisPet alAssessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review andmeta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerLancet Oncol2008910962972Open DOISearch in Google Scholar

22Schirripa M, Loupakis F, Lonardi S, Cremolini C, Bergamo F, Zagonel V, et al. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol. 2015; 26(12): 2503-2503.26371285SchirripaMLoupakisFLonardiSCremoliniCBergamoFZagonelVet alPhase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancerAnn Oncol201526122503250310.1093/annonc/mdv385Search in Google Scholar

23Yokota T, Sano T, Shimizu Y, Takahari D, Senda Y, Shimura M, et al. Pathological complete response of colorectal liver metastases following chemotherapy with S-l and oxaliplatin (SOX) in combination with bevacizumab: A case report. Oncol Lett. 2011; 2(2): 201-205.10.3892/ol.2011.256YokotaTSanoTShimizuYTakahariDSendaYShimuraMet alPathological complete response of colorectal liver metastases following chemotherapy with S-l and oxaliplatin (SOX) in combination with bevacizumab: A case reportOncol Lett201122201205Open DOISearch in Google Scholar

24Arata R, Itamoto T, Ikeda S, Nakahara H, Oshita A, Shinozaki K, et al. Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case. Surg Case Rep. 2016; 2(1): 106.2768666610.1186/s40792-016-0231-9ArataRItamotoTIkedaSNakaharaHOshitaAShinozakiKet alPathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual caseSurg Case Rep201621106Search in Google Scholar

25Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi S, Luppi G, et al. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol. 2009; 2:35.10.1186/1756-8722-2-35MalavasiNPontiGDepenniRBertoliniFZironiSLuppiGet alComplete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case reportJ Hematol Oncol2009235Open DOISearch in Google Scholar

26Naiken SP, Toso C, Rubbia-Brandt L, Thomopoulos T, Roth A, Mentha G, et al. Complete path-ological response (ypTONOMO) after preoperative chemotherapy alone for stage IV rectal cancer. BMC Surg. 2014; 14: 4.2443809010.1186/1471-2482-14-4NaikenSPTosoCRubbia-BrandtLThomopoulosTRothAMenthaGet alComplete path-ological response (ypTONOMO) after preoperative chemotherapy alone for stage IV rectal cancerBMC Surg2014144Search in Google Scholar

27Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomised trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10): 1215-1223.10.1002/bjs.5506BujkoKNowackiMPNasierowska-GuttmejerAMichalskiWBebenekMKryjMLong-term results of a randomised trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancerBr J Surg2006931012151223Open DOISearch in Google Scholar

28Van Vledder MG, Pawlik TM, Munireddy S, Hamper U, De Jong MC, Choti MA. Factors determining the sensitivity of intraoperative ultrasonography in detecting colorectal liver metastases in the modern era. Ann Surg Oncol. 2010; 17(10):2756-2763.2051768210.1245/s10434-010-1108-yVanVledder MGPawlikTMMunireddySHamperUDeJong MCChotiMAFactors determining the sensitivity of intraoperative ultrasonography in detecting colorectal liver metastases in the modern eraAnn Surg Oncol2010171027562763Search in Google Scholar

29Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302(21): 2338-2344.10.1001/jama.2009.175519952320ChunYSVautheyJNBoonsirikamchaiPMaruDMKopetzSPalavecinoMet alAssociation of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastasesJAMA20093022123382344Open DOISearch in Google Scholar